KWON, YONG TAE,权 容兑,權 容兌,JI, CHANG HOON,池昌勋,池昌勛,GANIPISETTI, SRINIVASRAO,喇 悟,KIM, HEE YEON,金希姸,MUN, SU RAN,文修兰,文修蘭,JUNG, CHAN HOON,郑灿勳,鄭燦勳,JUNG, EUI JUNG,郑宜静,鄭宜靜,SUNG, KI WOON,成基云
申请号：
TW108126217
公开号：
TW202019399A
申请日:
2019.07.24
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.本發明係關於一種新穎的p62配體化合物、其立體異構體、水合物、溶劑合物或前藥，及包含其作為活性成分之用於預防或治療蛋白質構象病的醫藥或食品組成物。根據本發明之p62配體化合物可有效地用作一種用於藉由活化細胞中之自噬且因此選擇性地消除活體內蛋白質、細胞器以及聚集體來預防、改善或治療各種蛋白質構象病之醫藥組成物。
